DDX41 Variant Discrimination via Retroviral Rescue Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to effectively discriminate between functionally defective and benign DDX41 variants, which are crucial for clinical genetic curation and monitoring the progression of myeloid malignancies.
Innovation Solution
An in vitro genetic rescue assay is developed to identify functionally defective DDX41 variants by comparing the mRNA expression of specific transcripts in cells infected with retroviruses expressing DDX41 variants of uncertain significance (VUS) to those expressing wild-type DDX41, using differential expression analysis to determine pathogenic variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to analyze DDX41 variants, then genetic testing can be performed, but the ability to discriminate between functionally defective and benign variants is insufficient
Solution Approach 1:
The patent introduces an intermediary assay system (retroviral rescue assay) that mediates between the genetic variant and the measurement outcome. The assay uses retroviral infection to deliver wild-type DDX41 cDNA into patient-derived cells, creating an intermediate state that allows functional comparison between variants and enables precise discrimination of pathogenicity
Solution Approach 2:
The patent changes the measurement parameter from simple genetic presence/absence to functional activity assessment. By measuring DDX41 protein expression levels, splicing efficiency, and cellular rescue phenotypes, the assay transforms the evaluation from qualitative genetic testing to quantitative functional analysis, achieving superior discrimination accuracy
2Quantity of substance
If comprehensive genetic testing is performed to identify all DDX41 variants, then more variants are detected, but the clinical utility is limited without functional discrimination capability
Solution Approach 1:
The patent implements a feedback mechanism where the functional assay results feed back into the interpretation of genetic test findings. The rescue assay provides experimental validation that feeds back to confirm or refute the predicted pathogenicity of variants, transforming raw genetic data into clinically actionable information about functional significance
Data Source
AI summary
Described herein is an in vitro genetic rescue assay for identifying a functionally defective DDX41 variant which includes identifying a DEAD-Box Helicase 41 (DDX41) variant of uncertain significance (VUS), infecting a first Ddx41+/− cell with a retrovirus expressing the DDX41-VUS, infecting a second Ddx41+/− cell with a retrovirus expressing a wild type control DDX41, growing the first and second infected cells in culture for a period of time and quantitating mRNA expression of a DDX41-regulated transcript in both the first and second infected cells after the period of time, calculating a differential expression of the DDX41-regulated transcript for the first infected cell compared the second infected cell, and identifying the DDX41-VUS as the functionally defective DDX41 variant wherein a change in the differential expression is 1.5-fold or greater. The identified functionally defective DDX41 variants can be used in methods of monitoring a patient for the development/progression of myeloid malignancy.